Abstract:Leishmaniasis is a parasite disease prevalent in 88 nations worldwide, causing high morbidity and mortality in most developing countries. Since no vaccine or pharmaceutical treatment with the best therapeutic window is available, the World Health Organization has listed Leishmaniasis as a priority disease. The enzyme heat shock protein 83 (Hsp83), which is frequently found in cells, catalyzes cellular biological pathways to carry out tasks such as protein folding, intracellular protein trafficking, acquired thermotolerance, differentiation, adaptability, pathogenicity, persistence in the host cell and preventing proteins from being damaged by heat and other stresses. Therefore, HSP actively rewires cellular functions and signalling pathways, which is crucial for cell survival. Inhibition of HSP may interfere with pathogenesis and virulence by impairing several processes. Therefore, L. donovani heat shock protein 83 (LdHsp83) has been suggested as a potential leishmaniasis therapeutic target. Thus, in this study, we built the structure of HSP83 by homology modelling. We used Leishmania primary HSP90 crystal structure (PDB ID 3HJCA) as a template for constructing 3D models of LdHSP83 by comparative modelling approach using SWISS-MODEL, Phyre, GENO 3D program server and Prime 2.1 (Maestro 9.1, Schrodinger 2010) program tool. Based on overall stereochemical quality (PROCHECK, DOPE, Verify 3D), the best model was selected and further used for structural analysis. The energy-minimized, refined and characterized model was further investigated for antileishmanial activity with currently available antileishmanial drugs and enumerated virtual library of chemical compounds through a docking approach. A few combinations, including oxmetidine, had an excellent binding affinity with the Hsp83, as indicated by Glide Score (G Score) and Gold Fitness Score. These potential inhibitors were further studied for SAR and ADMET properties, respectively, by TSAR 3.3 and Qikprop 2.3, indicating the safety and efficacy of these compounds. Once preclinically and clinically examined, these compounds may further be implemented in leishmaniasis therapy.

Integrated subtractive genomics and structure-based approach to unravel the therapeutic drug target of Leishmania species

Computational multi‐target approach to target essential enzymes of Leishmania donovani using comparative molecular dynamic simulations and MMPBSA analysis

Investigation into in silico and in vitro approaches for inhibitors targeting MCM10 in Leishmania donovani: a comprehensive study

Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors

An integrative approach using systems biology, mutational analysis with molecular dynamics simulation to challenge the functionality of a target protein

Structural Analysis and In-Silico Inhibitor Interaction Studies of Leishmania donovani Heat-Shocked Proteins 83 (HSP83)

A computer-aided approach to identify novel Leishmania major protein disulfide isomerase inhibitors for treatment of leishmaniasis

Identification of novel anti‐leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach

Harnessing computational and experimental approaches to identify potent hits against Leishmania donovani sterol C-24 methyltransferase from ChemBridge library

Identification of potential inhibitor against Leishmania donovani mitochondrial DNA primase through in-silico and in vitro drug repurposing approaches

Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases

Repurposing FDA approved drugs against Sterol C-24 methyltransferase of Leishmania donovani: A dual in silico and in vitro approach

Computer-aided drug design approaches applied to screen natural product’s structural analogs targeting arginase in Leishmania spp

Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani

Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach

Targeting with Structural Analogs of Natural Products the Purine Salvage Pathway in Leishmania (Leishmania) infantum by Computer-Aided Drug-Design Approaches

Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism

Development of novel dual-target drugs against visceral leishmaniasis and combinational study with miltefosine

Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling

Repositioning FDA-Approved Drug Against Chagas Disease and Cutaneous Leishmaniosis by Structure-Based Virtual Screening

Leishmanicidal Activity of an In Silico-Screened Novel Inhibitor against Ascorbate Peroxidase of Leishmania donovani